China Nepstar Chain Drugstore Reports Third Quarter 2011 Financial Results

SHENZHEN, China, Nov. 28, 2011 /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD) ("Nepstar" or the "Company"), the largest retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the third quarter ended September 30, 2011.

Financial Highlights

For the quarter ended September 30, 2011:

  • Revenue increased 1.9% to RMB608.6 million (US$95.4 million), compared to revenue of RMB597.0 million in the third quarter of 2010
  • Gross margin was 47.5%, compared to 49.8% in the third quarter of 2010
  • Same store sales increased by 6.5% over the prior year's period
  • Net income was RMB1.2 million (US$0.2 million), compared to RMB10.4 million in the third quarter of 2010
  • Net cash flow from operations was RMB34.1 million (US$5.4 million), compared to RMB 38.4 million in the third quarter of 2010

Mr. Fuxiang Zhang, Chief Executive Officer of Nepstar, commented, "Our strategy of positioning Nepstar as a neighborhood store for one-stop pharmacy and convenience shopping is executed in the midst of highly publicized Chinese healthcare reform, which presents new dynamics of both challenges and opportunities. On the one hand, our gross margin has been facing significant downward pressure due to the price cap policies covering increasing number of pharmaceuticals in the market. On the other hand, we observe that the reform is also exerting pressure on pharmaceutical manufacturers. We see this as an opportunity to reinforce our pharmacy business, as we believe more pharmaceutical manufacturers are looking to retail channels to leverage their production capacity.

"At Nepstar, we continue to work on introducing new products in both pharmaceutical and non-pharmaceutical categories, streamlining our operations and growing same store sales to stand the headwind of the general operational environment. During the quarter, we have established a stringent model to track and evaluate store productivity. While we have increased same store sales, we also scaled back non-performing stores, as operating costs have been steadily rising."

Third Quarter Results

During the third quarter of 2011, the Company opened 10 new stores and closed 63 stores. As of September 30, 2011, Nepstar had a total of 2,458 stores in operation.

Revenue for the quarter increased 1.9% to RMB608.6 million (US$95.4 million), compared to revenue of RMB597.0 million for the same period in 2010. Increased sales of newly introduced convenience products continued to offset the negative impact on drug sales from ongoing healthcare reform that has led to price cuts and the diversion of patients from drugstores.

Third quarter revenue contribution from prescription drugs was 20.7%, OTC drugs was 34.9%, nutritional supplements was 18.2%, traditional Chinese herbal products was 3.9% and convenience and other products was 22.3%. During the third quarter of 2011, the Company introduced 45 new stock keeping units (SKUs) within the convenience products category.

Same store sales (for 2,179 stores opened before December 31, 2009) for the third quarter of 2011 increased by 6.5% compared to the same period in 2010. This growth was mainly attributable to increased sales of convenience products and other new non-pharmaceutical products introduced since the second half of 2010.

Nepstar's portfolio of private label products included 1,856 products as of September 30, 2011. Sales of private label products represented approximately 30.9% of revenue and 43.2% of gross profit for the third quarter of 2011.

Third quarter gross profit was RMB289.3 million (US$45.4 million), compared to RMB297.4 million in the same period of 2010. Gross profit margin in the third quarter of 2011 was 47.5%, compared to 49.8% in the same period of 2010 and 47.8% in the second quarter of 2011. The decline in gross profit margin was mainly due to price reductions on essential drugs and changes in revenue mix as the Company introduced more convenience products with lower gross profit margin. The Company continued to make efforts to provide quality private label products at reasonable prices in convenience products category. In the third quarter, private label products' contribution to the convenience products category reached 28.0%, which helped maintain a reasonably favorable gross profit margin level on sales of convenience products.

Sales, marketing and other operating expenses as a percentage of revenue in the third quarter of 2011 increased to 42.6% compared to 41.9% in the same period of 2010. The increase was primarily due to higher rental and labor costs owing to a general inflationary economic environment.

General and administrative expenses as a percentage of revenue in the third quarter of 2011 were 4.2%, compared to 5.5% in the same period of 2010. The lower G&A expenses were mainly due to rigorous cost control measures and reduced share based expenditures, etc.

As a result of the factors discussed above, income from operations in the third quarter of 2011 was RMB3.0 million (US$0.5 million), compared to RMB14.5 million in the same period of 2010.

Interest income for the third quarter of 2011 was RMB6.1 million (US$1.0 million), compared to RMB5.5 million in the same period of 2010. The increase in interest income was mainly due to an increase in interest rates by the Chinese government. Dividend income from cost method investments was RMB0.7 million (US$0.1 million) for the third quarter of 2011, compared to zero in the same quarter of 2010. Equity income of an equity method investee was a loss of RMB0.6 million (US$0.1 million), compared to a gain of RMB2.3 million in the same quarter of 2010.

Nepstar's effective tax rate was 87.0% for the third quarter of 2011, compared to 53.2% for the same period in 2010. Other than the impact from non-deductible expenses, the high effective tax rate in the third quarter of 2011 was partially due to the valuation allowance made on deferred tax assets arising from the tax loss carryforwards of the loss-making subsidiaries. It is also due to the decreased profitability of the profitable subsidiaries, which resulted in lower consolidated income before income tax.

Net income for the third quarter of 2011 was RMB1.2 million (US$0.2 million), which represented RMB0.01 (US$0.002) basic and diluted earnings per American Depositary Share ("ADS"). This compares to a net income of RMB10.4 million, which represented RMB0.10 basic and diluted earnings per ADS in the same period of 2010. The total number of outstanding ordinary shares of the Company as of September 30, 2011 was 204.4 million. The weighted average number of ordinary shares in the third quarter of 2011 was 206.1 million. Each ADS represents two ordinary shares of the Company.

As of September 30, 2011, Nepstar's total cash, cash equivalents and bank deposits were RMB975.6 million (US$153.0 million) and its shareholders' equity was RMB1.35 billion (US$211.6million).

In the third quarter of 2011, net cash flow from operations was RMB34.1 million (US$5.4 million).

Business Outlook

"We are committed to further broadening our product mix in both pharmaceutical and non-pharmaceutical categories as we are encouraged by the same store sales growth contributed by new products we added since the second half of last year. The ongoing healthcare reform brought new dynamics to our strategy. We look forward to taking advantage of the policy-driven pricing pressure to drug manufacturers and increasing our own prescription and OTC drugs coverage. In the fourth quarter, we are also reinforcing training to our floor staff to improve store productivity. Overall, we remain confident in the long-term prospects of the Company and the consumer healthcare market in China," Mr. Zhang concluded.

Conference Call Information

The Company will host a conference call, to be simultaneously webcasted, on Monday, November 28, 2011 at 8:00 a.m. Eastern Time / 9:00 p.m. Beijing Time. Interested parties may participate in the conference call by dialing +1-877-407-9210 (North America) or +1-201-689-8049 (International) approximately five minutes before the call start time. A live web cast of the conference call will be available on the Nepstar website at www.nepstar.cn.

A replay of the call will be available shortly after the conclusion of the conference call through December 4, 2011 at 11:59 p.m. Eastern Time or December 5, 2011 at 12:59 p.m. Beijing Time. An archived Web cast of the conference call will be available on the Nepstar website at http://www.nepstar.cn. Interested parties may access the replay by dialing +1-877-660-6853 (North America) or +1-201-612-7415 (International) and entering account number 286 and conference ID number 382739.

About China Nepstar Chain Drugstore Ltd.

China Nepstar Chain Drugstore Ltd. (NYSE: NPD) is China's largest retail drugstore chain based on the number of directly operated stores. As of September 30, 2011, the Company had 2,458 stores across 74 cities, one headquarter distribution center and 14 regional distribution centers in China. Nepstar uses directly operated stores, centralized procurement and a network of distribution centers to provide its customers with high-quality, professional and convenient pharmacy services and a wide variety of other merchandise, including OTC drugs, nutritional supplements, herbal products, personal care products, family care products, and convenience products including consumables. Nepstar's strategy of centralized procurement, competitive pricing, customer loyalty programs and private label offerings has enabled it to capitalize on the robust economic growth in China and to take advantage of the demographic trend in China to achieve a strong brand and leading market position. For further information, please go to http://www.nepstar.cn.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release and the Company's strategic operational plans and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Exchange Rate Information

The United States dollar (US$) amounts disclosed in this press release are presented solely for the convenience of the reader. Translations of amounts from RMB into United States dollars for the convenience of the reader were calculated at the certified exchange rate of US$1.00 = RMB6.3780 on September 30, 2011 as set forth in the H.10 weekly statistical release of the Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted into US$ at that rate on September 30, 2011, or at any other date. The percentages stated are calculated based on RMB amounts.

Contacts

Lucia Qian
China Nepstar Chain Drugstore Ltd.
Vice President, IR
Phone: +86-755-2641-4065
Email: qianrt@nepstar.cn

Dixon Chen
Grayling
Investor Relations
Tel: +1-646-284-9403
Email: dixon.chen@grayling.com

Ivette Almeida
Grayling
Media Relations
Tel: +1-646-284-9455
Email: ivette.almeida@grayling.com

Tables follow

China Nepstar Chain Drugstore Ltd.

Unaudited Condensed Consolidated Statements of Income

(amounts in thousands – except per-share data)






Three-month period ended


September 30,

September 30,

September 30,


2010

2011

2011


RMB

RMB

USD





Revenue

597,045

608,626

95,426

Cost of goods sold

(299,604)

(319,340)

(50,069)





Gross profit

297,441

289,286

45,357





Sales, marketing and other operating expenses

(249,990)

(259,540)

(40,693)

General and administrative expenses

(32,991)

(25,752)

(4,038)

Impairment losses of property and equipment

-

(1,012)

(159)





Income from operations

14,460

2,982

467





Interest income

5,537

6,101

957

Dividend income from cost method investments

-

682

107

Equity in income of an equity method investee

2,314

(630)

(99)





Income before income tax expense

22,311

9,135

1,432





Income tax expense

(11,875)

(7,948)

(1,246)





Net income attributable to




China Nepstar Chain Drugstore Ltd.

10,436

1,187

186





Basic earnings per ordinary share

0.050

0.006

0.001

Basic earnings per ADS

0.100

0.012

0.002

Diluted earnings per ordinary share

0.050

0.006

0.001

Diluted earnings per ADS

0.100

0.012

0.002




China Nepstar Chain Drugstore Ltd.

Unaudited Condensed Consolidated Balance Sheets

(amounts in thousands)






As of

As of

As of


December 31,

September 30,

September 30,


2010

2011

2011


RMB

RMB

USD

ASSETS




Current assets:




Cash, cash equivalents and bank deposits

1,139,796

806,562

126,460

Restricted cash

5,000

-

-

Accounts receivable, net of allowance for doubtful accounts

83,722

92,579

14,515

Amounts due from related parties

12,358

4,218

661

Prepaid expenses, deposits and other current assets

127,750

122,922

19,273

Inventories

433,265

404,196

63,373

Deferred tax assets

3,551

2,201

345





Total current assets

1,805,442

1,432,678

224,627





Non-current assets:




Bank deposits

-

169,000

26,497

Property and equipment, net

192,019

162,564

25,488

Rental deposits

41,811

40,354

6,327

Cost method investments

12,638

12,638

1,981

Equity method investment

35,151

35,149

5,511

Land use right

8,227

-

-

Intangible assets, net

2,919

3,176

498

Goodwill

51,089

51,819

8,125

Deferred tax assets

1,813

1,951

306

Deposits for acquisitions

2,000

1,000

157

Accrued interest income

-

1,152

181





Total non-current assets

347,667

478,803

75,071





TOTAL ASSETS

2,153,109

1,911,481

299,698





LIABILITIES AND SHAREHOLDERS' EQUITY




Current liabilities:




Accounts payable

313,773

325,409

51,021

Amounts due to related parties

24,461

18,462

2,895

Accrued expenses and other payables

131,330

119,519

18,739

Deferred income

26,102

13,007

2,039

Income tax payable

52,520

56,939

8,927





Total current liabilities

548,186

533,336

83,621





Non-current liabilities:




Deferred income

18,794

17,377

2,725

Deferred tax liabilities

16,922

10,892

1,708





Total non-current liabilities

35,716

28,269

4,433





Total liabilities

583,902

561,605

88,054





Shareholders' equity:




Share capital

164

162

25

Treasury stock

-

(1,267)

(199)

Additional paid-in capital

1,501,809

1,264,663

198,285

Accumulated other comprehensive loss

(41,563)

(40,747)

(6,389)

Retained earnings

108,797

127,065

19,922





Total shareholders' equity

1,569,207

1,349,876

211,644





TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

2,153,109

1,911,481

299,698





SOURCE China Nepstar Chain Drugstore Ltd.



RELATED LINKS
http://www.nepstar.cn

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.